Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Participant- and Investigator-blinded, Placebo-controlled, Single Ascending Dose and Multiple Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of INE963 in Healthy Participants

NCT04896632 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT04896632
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04896632 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Participant- and Investigator-blinded, Placebo-controlled, Single Ascending Dose and Multiple Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of INE963 in Healthy Participants
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 1
Overall status
Terminated
Start date
May 13, 2021
Completion date
November 24, 2022
Enrollment
64 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers